Xu M - Search Results

1

CRISPR-Cas9 for cancer therapy: Opportunities and challenges.

Chen M, Mao A, Xu M, Weng Q, Mao J, Ji J. Chen M, et al. Among authors: xu m. Cancer Lett. 2019 Apr 10;447:48-55. doi: 10.1016/j.canlet.2019.01.017. Epub 2019 Jan 23. Cancer Lett. 2019. PMID: 30684591 Review.

2

Piplartine suppresses proliferation and invasion of hepatocellular carcinoma by LINC01391-modulated Wnt/β-catenin pathway inactivation through ICAT.

Fan X, Song J, Zhao Z, Chen M, Tu J, Lu C, Wu F, Zhang D, Weng Q, Zheng L, Xu M, Ji J. Fan X, et al. Among authors: xu m. Cancer Lett. 2019 Sep 28;460:119-127. doi: 10.1016/j.canlet.2019.06.008. Epub 2019 Jun 14. Cancer Lett. 2019. PMID: 31207322

3

Applications and advances of CRISPR/Cas9 in animal cancer model.

Xu M, Weng Q, Ji J. Xu M, et al. Brief Funct Genomics. 2020 May 20;19(3):235-241. doi: 10.1093/bfgp/elaa002. Brief Funct Genomics. 2020. PMID: 32124927

4

miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression.

Chen M, Wu L, Tu J, Zhao Z, Fan X, Mao J, Weng Q, Wu X, Huang L, Xu M, Ji J. Chen M, et al. Among authors: xu m. EBioMedicine. 2018 Sep;35:142-154. doi: 10.1016/j.ebiom.2018.08.010. Epub 2018 Aug 13. EBioMedicine. 2018. PMID: 30111512 Free PMC article.

5

CPEB1 mediates hepatocellular carcinoma cancer stemness and chemoresistance.

Xu M, Fang S, Song J, Chen M, Zhang Q, Weng Q, Fan X, Chen W, Wu X, Wu F, Tu J, Zhao Z, Ji J. Xu M, et al. Cell Death Dis. 2018 Sep 20;9(10):957. doi: 10.1038/s41419-018-0974-2. Cell Death Dis. 2018. PMID: 30237545 Free PMC article.

6

LINC00460 promotes hepatocellular carcinoma development through sponging miR-485-5p to up-regulate PAK1.

Tu J, Zhao Z, Xu M, Chen M, Weng Q, Ji J. Tu J, et al. Among authors: xu m. Biomed Pharmacother. 2019 Oct;118:109213. doi: 10.1016/j.biopha.2019.109213. Epub 2019 Jul 31. Biomed Pharmacother. 2019. PMID: 31376654 Free article.

7

KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.

Liu X, Qiu R, Xu M, Meng M, Zhao S, Ji J, Yang Y. Liu X, et al. Among authors: xu m. Breast Cancer Res Treat. 2021 Sep;189(2):347-361. doi: 10.1007/s10549-021-06325-1. Epub 2021 Jul 8. Breast Cancer Res Treat. 2021. PMID: 34240274

8

A role for the NPM1/PTPN14/YAP axis in mediating hypoxia-induced chemoresistance to sorafenib in hepatocellular carcinoma.

Zhang D, Wu F, Song J, Meng M, Fan X, Lu C, Weng Q, Fang S, Zheng L, Tang B, Yang Y, Tu J, Xu M, Zhao Z, Ji J. Zhang D, et al. Among authors: xu m. Cancer Cell Int. 2022 Feb 8;22(1):65. doi: 10.1186/s12935-022-02479-0. Cancer Cell Int. 2022. PMID: 35135548 Free PMC article.

9

MicroRNA-34a Inhibition of the TLR Signaling Pathway Via CXCL10 Suppresses Breast Cancer Cell Invasion and Migration.

Xu M, Li D, Yang C, Ji JS. Xu M, et al. Cell Physiol Biochem. 2018;46(3):1286-1304. doi: 10.1159/000489111. Epub 2018 Apr 16. Cell Physiol Biochem. 2018. Retraction in: Cell Physiol Biochem. 2020;54(5):1097. doi: 10.33594/000000299. PMID: 29689563 Free article. Retracted.

10

FGFR4 Links Glucose Metabolism and Chemotherapy Resistance in Breast Cancer.

Xu M, Chen S, Yang W, Cheng X, Ye Y, Mao J, Wu X, Huang L, Ji J. Xu M, et al. Cell Physiol Biochem. 2018;47(1):151-160. doi: 10.1159/000489759. Epub 2018 May 10. Cell Physiol Biochem. 2018. PMID: 29763898 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22,018 results

Search Page

Filters